Rennes University Hospital
Rennes, 35033, France
NCT Number: NCT03910868
Prospective and monocentric pharmacokinetic study
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Rennes, 35033, France
Membrane transporters supporting tacrolimus at the lymphocyte level may play a role in the variability of the relationship between tacrolimus blood concentration and intracellular concentration, or may be the main explanatory factors. Nevertheless, most of the studies carried out on the subject, have been by genetic approach, neglecting in fact the membrane expression of these transporters, which could testify more to the real effect on the transport of tacrolimus. A better understanding of the cellular transport mechanisms of tacrolimus in the T lymphocyte could thus make it possible to identify sub-populations of patients under-exposed at the intra-lymphocyte level, despite satisfactory systemic exposure.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: During the consultation (between 2 and 24 months after the transplant)
The mRNA levels will be recorded as a cycle threshold difference between the studied gene, and the mean of two housekeeping genes (ACTB and B2M). The proteic expression of the studied transporters will be recorded as fluorescent intensity levels
Time frame: During the consultation (between 2 and 24 months after the transplant)
The mRNA levels will be recorded as a cycle threshold difference between the studied gene, and the mean of two housekeeping genes (ACTB and B2M). The proteic expression of the studied transporters will be recorded as fluorescent intensity levels
Time frame: During the consultation (between 2 and 24 months after the transplant)
Tacrolimus-related adverse effects as recorded on the medical record of the patient.
Time frame: During the consultation (between 2 and 24 months after the transplant)
Treatment outcome as recorded on the medical record of the patient.
Time frame: During the consultation (between 2 and 24 months after the transplant)
Co-medications as recorded on the medical record of the patient.
Time frame: During the consultation (between 2 and 24 months after the transplant)
Donor graft cf-DNA characterized the cell death marker, released from necrotic or apoptotic cells in the transplant organ, and may therefore be useful as a marker for graft injury. When its plasma concentration increases, it evidences that a lesion process occurs in the graft
Rennes University Hospital
Other
Study of the Impact of P-gp, MRP2, ENT-1 and CNT3 on the Blood Concentration / Intra-PBMC Concentration of Tacrolimus in Liver and Kidney Transplant Patients
Acronym: TRANS-TAC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01294020
Heart Transplantation, Intestine Transplantation
Brussels, Belgium
View Trial DetailsNCT05152628
Kidney Transplantation, Liver Transplantation
Beijing, China
View Trial DetailsNCT05153915
Kidney Transplantation, Liver Transplantation
Beijing, China
View Trial DetailsNCT04587024
Behavior, Health Behavior
Baltimore, Maryland, United States
View Trial Details